EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Developing anti-Müllerian hormone as an ovarian reserve biomarker

Bart C J M Fauser iD

Molecular Human Reproduction · 2026

DOI: 10.1093/molehr/gaag021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Human Reproduction, 2026. Verfasst von Bart C J M Fauser. Beteiligte Einrichtung: University of Utrecht & University Medical Center Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Anti-Mullerian Hormone, Ovarian Reserve, Ovarian Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first anti-Müllerian hormone (AMH) radioimmunoassay became available for clinical use in the early 2000s. This MHR Legacy Series review discusses key contributions from our own group towards establishing AMH as a robust ovarian reserve biomarker. Initial studies in female volunteers demonstrated decreasing serum AMH concentrations with increasing female age, along with a direct correlation between AMH levels and the number of antral follicles. The most relevant clinical conditions where measurements of serum AMH appear to be of great value include the diagnosis of various forms of ovarian dysfunction, especially polycystic ovary syndrome and premature ovarian insufficiency. In addition, a close correlation between initial serum AMH levels and ovarian response to standard stimulation for IVF has been firmly established, resulting in the development of a safe and effective AMH-based algorithm for individualized ovarian stimulation. Another area, beyond our own research, where AMH serum measurements have proven to be of great clinical significance is oncofertility. The capacity of AMH levels to predict fecundity—either spontaneous or following infertility treatment—or forecast age of menopause later in life remains uncertain and needs more well-designed, prospective, follow-up studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Mullerian HormoneOvarian ReserveOvarian DiseasesHumansAnimalsBiomarkersFemaleOvaryInfertility, Female

Stichwörter der Autor:innen

IVFanti-Müllerian hormonefecundityfollicleovarypolycystic ovary syndromepregnancypremature ovarian insufficiency

Substanzen

Anti-Mullerian HormoneBiomarkers

Autor:innen und Institutionen

  • University of Utrecht & University Medical Center Utrecht, Utrecht, The Netherlands.

ORCID-Profile: Bart C J M Fauser

Zitieren

APA

Fauser, B. C. J. M. (2026). Developing anti-Müllerian hormone as an ovarian reserve biomarker. Molecular Human Reproduction. https://doi.org/10.1093/molehr/gaag021

Vancouver

Fauser BCJM. Developing anti-Müllerian hormone as an ovarian reserve biomarker. Molecular Human Reproduction. 2026. doi:10.1093/molehr/gaag021

BibTeX
@article{Fauser2026,
  author = {Fauser, Bart C J M},
  title = {Developing anti-Müllerian hormone as an ovarian reserve biomarker},
  journal = {Molecular Human Reproduction},
  year = {2026},
  doi = {10.1093/molehr/gaag021}
}
Kostenlos starten →